Skip to main content

Table 4 Clinical phenotypes associated with various causative genes/molecular pathogenic changes in the current cohort of hereditary myopathies

From: Clinical and genetic evaluation of hereditary myopathies in an adult Saudi cohort

Clinical phenotype

Gene

N = 40

Limb-girdle weakness

DYSF

4

FKRP

3

CAPN3

2

SGCA

2

SGCD

1

ANO5

1

Limb-girdle weakness + calf hypertrophy

DMD

7

Limb-girdle weakness + contractures

LMNA

2

COL6A1

2

Limb-girdle weakness + scoliosis

MYO18B

1

Limb-girdle weakness + scapular winging

TYMP

1

Clinical myotonia + distal muscle weakness

DMPK

7

Clinical myotonia

CLCN1

1

Clinical myotonia + skeletal deformity

HSPG2

1

Early respiratory muscle weakness + distal weakness

TTN

1

Exertional myalgia and cramps

AGL

2

LAMP2

1

Recurrent rhabdomyolysis

PGAM2

1

Clinical phenotype

Molecular pathogenic change

N = 2

Facioscapulohumeral weakness

Reduction of D4Z4 repeat array units

2

  1. AGL, amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase; ANO5, anoctamin-5; CAPN3, calpain-3; CLCN1, chloride voltage-gated channel 1; COL6A1, collagen Type VI Alpha 1 Chain; DMD, dystrophin; DMPK, dystrophia myotonica protein kinase; DYSF, dysferlin; FKRP, fukutin-related protein; HSPG2, heparan sulfate proteoglycan 2; LAMP2, lysosomal associated membrane protein 2; LMNA, lamin A/C; MYO18B, myosin XVIIIB; PGAM2, phosphoglycerate mutase 2; SGCA, sarcoglycan alpha; SGCD, sarcoglycan delta; TTN, titin; TYMP, thymidine phosphorylase